Patent Grant
9174067
The present invention relates to systems and methods for generating light. More specifically, the present invention relates to a lighting system and method for emitting light to treat light treatable conditions.
It is known that a person's physiology and wellbeing can be influenced by phototherapy. The light entering the eye of a person may impact the production of melatonin, which increases during darkness, and can be reduced by the influence of light. Phototherapy may be also used to treat conditions such as acne, skin cancer, psoriasis, seasonal affective disorder and to advance or delay circadian rhythms. Light can also be tailored to positively or negatively enhance the presence of certain colors by altering the wavelength of the emitted light. Individuals that suffer from color blindness may prefer to have the light tailored to their particular visual abilities.
A phototherapy device is disclosed, for example, in U.S. Patent Application Publication No. 2012/0316623 by Ii, et al. The Ii et al. reference discloses a phototherapy device that can irradiate an affected part of a patient's body. U.S. Patent Application Publication No. 2006/0167532 by Parker discloses a phototherapy treatment device for applying area lighting to a wound. U.S. Pat. No. 8,069,857 by Chung et al. discloses a phototherapy method. The Chung et al. reference discloses a method of providing phototherapy to a patient.
These devices utilize phototherapy but they do not tailor the light treatment to an individual, based upon the viewing characteristics and abilities of the individual. Therefore, a need exists to enable a luminaire to produce light that is tailored to an individual's specific vision abilities and treat light treatable conditions.
This background information is provided to reveal information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.
Provided herein are systems and methods that address the above-identified problems. More specifically, the present invention advantageously provides a method and system for treating a light treatable condition. The system may enable a luminaire to be tailored to emit light of particular wavelengths where the wavelengths selected for emission may be selected based upon a diagnosis or may also be selected based upon the user's requests and preferences. Furthermore, the tailoring of the luminaire's light production enables a user to have a more enjoyable visual experience by enhancing the colors that the user would find most pleasing.
These and other features, benefits and advantages are provided by a system for treating a light treatable condition that include a luminaire which may be configured to emit diagnostic output spectra and a sensor which may be configured to measure a biotic response to the diagnostic output spectra to define a measured biotic response. The system may also include a computer in electrical communication with the luminaire and the sensor which may utilize the measured biotic response to determine a prescribed output spectra that is responsive to treat the light treatable condition. The luminaire may be configurable to emit the prescribed output spectra by receiving an instruction from the computer.
The measured biotic response may be a retinal response, an eye spectral response and/or a measurement of the pupillary light reflex. In an embodiment of the system, the prescribed output spectra may be based, at least in part, on the visual acuity of a patient. In another embodiment, a computer may be configured so that the prescribed output spectra for the patient is based on a visual acuity of the patient, the measured biotic response, and/or the patient's light preferences.
The prescribed output spectra may be transmittable to a patient device. The system may also include a second luminaire that is configurable to emit the prescribed output spectra based on receipt of instructions from the computer. The prescribed output spectra may also be responsive to a task performed by a patient and/or the time of day during which the patient will observe the prescribed output spectrum. In an embodiment of the system where the prescribed output spectra is responsive to the time of day during which the patient may observe the prescribed output spectra, the luminaire may comprise an autonomous clock configured to cause the luminaire to emit the prescribed output spectra at an indicated time of the day.
A method aspect for the present invention may be for treating a condition in a patient having a light treatable condition. The method may include exposing the patient to diagnostic output spectra and determining the patient's response to the diagnostic output spectra to define a measured patient's response. The method may also include determining a diagnosis of the patient based, at least in part, on the patient's response to the diagnostic output spectra. The method may further include determining a prescribed output spectra that is responsive to the diagnosis, and configuring a luminaire to emit the prescribed output spectra.
The accompanying drawings, which are incorporated herein, form part of the specification. Together with this written description, the drawings further serve to explain the principles of, and to enable a person skilled in the relevant art(s), to make and use an LED lighting system in accordance with the present invention. In the drawings, like reference numbers indicate identical or functionally similar elements.
The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Those of ordinary skill in the art will realize that the following embodiments of the present invention are only illustrative and are not intended to be limiting in any way. Other embodiments of the present invention will readily suggest themselves to such skilled persons having the benefit of this disclosure. Like numbers refer to like elements throughout.
In the interest of clarity, not all of the routine features of the implementations described herein are shown and described. It will, of course, be appreciated that in the development of any such actual implementation, numerous implementation-specific decisions must be made in order to achieve the developer's specific goals, such as compliance with application- and business-related constraints, and that these specific goals will vary from one implementation to another and from one developer to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking of engineering for those of ordinary skill in the art having the benefit of this disclosure.
Referring now to
The system 25 for treating a light treatable condition may include a luminaire programming station 7, which may be utilized to program a luminaire to emit a light suitable for treating a light treatable condition. More particularly, a luminaire may be placed inside the luminaire programming station 7 where it may receive its instructions from the computer 15 via wired connection 8. More information regarding the programming of the luminaire may be found in U.S. patent application Ser. No. 13/751,180, which is incorporated hereinabove.
Another embodiment of the invention may enable the computer to communicate with the luminaire programming station 7 via a wireless connection. The head support unit 9 and forehead rest 10 may enable a patient or user to comfortably place their head in position for an eye examination. Accordingly, those skilled in the art will appreciate that the present invention contemplates that data and/or instructions to program a luminaire to emit a light suitable for treating a light treatable condition may be transmitted to the luminaire wirelessly. This is possible when using a luminaire adapted to receive data wirelessly and, more specifically, programming data.
The programming data may, for example, be directed to a wavelength of the light to be emitted from the luminaire to treat the light treatable condition. Those skilled in the art will appreciate that different wavelengths of light emitted from a luminaire may be suitable to treat various light treatable conditions. For example, in the case of colorblindness, emitting a particular wavelength of light may enable a person who may not be able to view blue colors, for example, to once again view blue colors due to the effect of the wavelength of the light emitted from the luminaire.
Referring now to
The optical diagnostic system 11a may include a luminaire integrated into the system that may emit diagnostic output spectra into the eyes of the patient 12. The diagnostic output spectra may have a spectral power distribution configured to generate a biotic response in the eyes of the patient 12. More specifically, the diagnostic output spectra may have a spectral power distribution that, when incident upon the eyes of the patient 12, may generate a biotic response that is indicative of a light-treatable condition. The optical sensor system 11b may measure a biotic response to the diagnostic output spectra. The measured response may define a measured biotic response. The computer 15, which is in communication with each luminaire of 11a and the optical sensor system 11b, may analyze the measured biotic response to determine whether a light-treatable condition is detected. If a light-treatable condition is detected, the computer 15 may further determine an output spectrum or spectra that is responsive to treat a light treatable condition, being defined as a prescribed output spectra. The luminaire of 11a may be configurable to emit the prescribed output spectra by receiving an instruction from the computer 15. More specifically, the luminaire of 11a may include a light source that is operable to emit a light having a spectral power distribution that conforms to the prescribed output spectra. Moreover, the luminaire of 11a may be configured so as to be programmable to operate the light source to emit light having a spectral power distribution conforming to the prescribed output spectra. More information regarding the programming of the luminaire may be found in U.S. patent application Ser. No. 13/751,180, which is incorporated hereinabove.
The measured biotic response may be a retinal response, an eye spectral response and/or a pupillary light reflex. These biotic responses are exemplary only, and any biotic response may also include any optical response of a patient that is detectable by optical sensor system 11b and may be included as a measured biotic response. The pupillary light reflex response may also include pupil size measurements which may measure how the pupil dilates in response to diagnostic output spectra.
In an embodiment of the system 25 according to the present invention, the system may be configured to alleviate light treatable conditions such as color blindness. Color blindness is a deficiency of color vision. There is no actual blindness but there is a deficiency of color vision. The most usual cause is a fault in the development of one or more sets of retinal cones that perceive color in light and transmit that information to the optic nerve. Color blindness can also be produced by physical or chemical damage to the eye, the optic nerve, or parts of the brain. For example, people with achromatopsia suffer from a completely different disorder, but are nevertheless unable to see colors.
If a patient suffers from color blindness, the luminaire of 11a may be programmed to emit light spectra of a wavelength that is discernible by the patient. For example, a patient that suffers from red-green color blindness may receive a luminaire that emits light that would make red or green colors appear to be a different color so that the patient may perceive the existence of multiple colors.
Skilled artisans will recognize that the luminaire of 11a may be configured to emit light spectra of any color as defined by the CIE 1931 XYZ color space. For purposes of definition, the CIE 1931 XYZ color space, created by the International Commission on Illumination, is a red-green-blue (RGB) color space that may be characterized in three dimensions by tristimulus values which represent the luminance and chromaticity of a color (incorporated herein by reference). More information regarding the emission of light spectra of any color may be found in U.S. patent application Ser. No. 13/737,606 titled Tunable Light System and Associated Methods filed Jan. 9, 2013, the content of which is incorporated herein by reference in its entirety.
The prescribed output may be based at least in part on the visual acuity of a patient 12. Visual acuity defines the sharpness of vision and is measured by the ability to discern letters or numbers at a given distance. The optical sensor system 11a may determine the acuity of the patient depending on the responses to certain questions and stimuli in addition to the use of diagnostic output spectra. When the visual acuity of the patient is determined, the luminaire of 11a may be programmed to emit the prescriptive output spectra that alleviate the poor visual acuity experienced by the patient.
The controller or user interface 3 may include a user interface that may be part of the computer 15 and may be configured to receive a patient's light preferences. The controller or user interface 3 may enable the computer 15 to be operated via a keyboard, mouse, pointer, touch screen input system, or any other input device. A user may utilize the controller or user interface 3 to select various operations on the examination system 2.
The computer 15 may also be further configured so that the prescribed output spectra for the patient 12 may be based on the patient's light preferences. The prescribed output spectra may also be based at least in part on a task performed by a patient or the time of day during which the patient will observe the prescribed output spectrum.
A patient's light preferences may include a preference for a particular shade or hue of a color. For example, a user may like colors with a reddish tint. As a result, a luminaire may be programmed for that user that adds more red to its emitted colors by adding light spectra of a particular wavelength into the luminaire's emissions. Furthermore, a user may like light of a particular color temperature. Accordingly, the luminaire may be programmed to emit light having a spectral power distribution that forms a metamer that may be perceived as the preferred color temperature. Similarly, the patient's light preferences may indicate that the patient does not like a particular color or shade of colors. As a result, a luminaire may be programmed to negative the effect or presence of colors not pleasing to the user by removing light spectra of a particular wavelength from the luminaire's emissions.
The patient's tasks may also influence the prescriptive output spectra. For example, tasks requiring a higher CRI or the ability to distinguish between colors that are almost imperceptible by a patient, a luminaire may be programmed to emit prescribed output spectra of a particular wavelength to assist the patient and improve their vision in that regard.
Additionally, the patient's light preferences may indicate a light-treatable condition such as insomnia caused by melatonin suppression. In such examples, the prescribed output spectra may have a spectral power distribution that excludes wavelengths of light associated with melatonin suppression. More information regarding melatonin suppression and its avoidance may be found in U.S. patent application Ser. No. 13/652,207, which is incorporated by reference hereinabove.
In an alternative embodiment, the luminaire may include an autonomous clock so that the luminaire may emit the prescribed output spectra at an indicated time of day. Therefore, if a patient prefers to use a luminaire at a particular time of day, the luminaire may be programmed to automatically emit the prescribed output spectra at that time. As a result, the patient will not have to worry about switching the luminaire on or off when they would typically prefer to utilize the luminaire. In some embodiments, the autonomous clock may be an atomic clock.
Referring to
In an alternative embodiment, the examination system 2 may also include a network or cloud to which the computer 15 and medical database is connected. The medical database may include medical information that may be utilized to diagnose a medical condition. The luminaire may be configurable to emit a prescribed output spectra responsive to treat the light treatable condition where the computer 15 utilizes the medical database to determine the prescribed output spectra to treat the light treatable condition. The computer 15 may be configured to determine a diagnosis based at least in part on the biotic response to the diagnostic output spectra.
Referring to
Referring now to
In a method aspect of the invention, the measured patient's response may include a retinal response, eye spectral response or a pupillary light reflex. The prescribed output spectra may be based upon the visual acuity of the patient.
In a further method aspect of the invention, the computer 15 may be configured to receive information regarding the patient's light preferences via the user interface 3 and also receive those light preferences.
In another method aspect of the invention, the prescribed output spectra may be responsive to a task performed by a patient and/or a time of day during which the patient will observe the prescribed output spectrum. The computer may be further configured to determine prescriptive output spectra responsive to the patient's visual acuity, the patient's biotic response and the patient's light preferences.
Some of the illustrative aspects of the present invention may be advantageous in solving the problems herein described and other problems not discussed which are discoverable by a skilled artisan.
While the above description contains much specificity, these should not be construed as limitations on the scope of any embodiment, but as exemplifications of the presented embodiments thereof. Many other ramifications and variations are possible within the teachings of the various embodiments. While the invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best or only mode contemplated for carrying out this invention. Also, in the drawings and the description, there have been disclosed exemplary embodiments of the invention and, although specific terms may have been employed, they are unless otherwise stated used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention therefore not being so limited. Moreover, the use of the terms first, second, etc. do not denote any order or importance, but rather the terms first, second, etc. are used to distinguish one element from another. Furthermore, the use of the terms a, an, etc. do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item.
Many modifications and other embodiments of the invention will come to the mind of one skilled in the art having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is understood that the invention is not to be limited to the specific embodiments disclosed.
This application is a continuation-in-part of U.S. patent application Ser. No. 13/652,207 filed Oct. 15, 2012, entitled LED LAMP FOR PRODUCING BIOLOGICALLY-CORRECTED LIGHT, and is related to U.S. patent application Ser. No. 13/751,180 filed Jan. 28, 2013, entitled PROGRAMMABLE LUMINAIRE SYSTEM, the entire contents of each of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4691341 | Knoble | Sep 1987 | A |
| 5046494 | Searfoss et al. | Sep 1991 | A |
| 5189412 | Mehta | Feb 1993 | A |
| 5319301 | Callahan et al. | Jun 1994 | A |
| 5345143 | Little | Sep 1994 | A |
| 5523878 | Wallace et al. | Jun 1996 | A |
| 5563422 | Nakamura et al. | Oct 1996 | A |
| 5680230 | Kaburagi et al. | Oct 1997 | A |
| 5704701 | Kavanagh et al. | Jan 1998 | A |
| 5813753 | Vriens et al. | Sep 1998 | A |
| 5936599 | Reymond | Aug 1999 | A |
| 5997150 | Anderson | Dec 1999 | A |
| 6028396 | Morrissey, Jr. | Feb 2000 | A |
| 6140646 | Busta et al. | Oct 2000 | A |
| 6259572 | Meyer, Jr. | Jul 2001 | B1 |
| 6341876 | Moss et al. | Jan 2002 | B1 |
| 6356700 | Strobl | Mar 2002 | B1 |
| 6450652 | Karpen | Sep 2002 | B1 |
| 6459919 | Lys et al. | Oct 2002 | B1 |
| 6528954 | Lys et al. | Mar 2003 | B1 |
| 6561656 | Kojima et al. | May 2003 | B1 |
| 6577080 | Lys et al. | Jun 2003 | B2 |
| 6586882 | Harbers | Jul 2003 | B1 |
| 6594090 | Kruschwitz et al. | Jul 2003 | B2 |
| 6733135 | Dho | May 2004 | B2 |
| 6734639 | Chang et al. | May 2004 | B2 |
| 6762562 | Leong | Jul 2004 | B2 |
| 6767111 | Lai | Jul 2004 | B1 |
| 6798154 | Sullivan et al. | Sep 2004 | B1 |
| 6817735 | Shimizu et al. | Nov 2004 | B2 |
| 6853150 | Clauberg et al. | Feb 2005 | B2 |
| 6870523 | Ben-David et al. | Mar 2005 | B1 |
| 6871982 | Holman et al. | Mar 2005 | B2 |
| 6876007 | Yamazaki et al. | Apr 2005 | B2 |
| 6902296 | Searfoss, III | Jun 2005 | B2 |
| 6949894 | Sullivan et al. | Sep 2005 | B1 |
| 6965205 | Piepgras | Nov 2005 | B2 |
| 6967761 | Starkweather et al. | Nov 2005 | B2 |
| 6974713 | Patel et al. | Dec 2005 | B2 |
| 7008559 | Chen | Mar 2006 | B2 |
| 7014336 | Ducharme et al. | Mar 2006 | B1 |
| 7034934 | Manning | Apr 2006 | B2 |
| 7042623 | Huibers et al. | May 2006 | B1 |
| 7055994 | Martin | Jun 2006 | B2 |
| 7058197 | McGuire et al. | Jun 2006 | B1 |
| 7066628 | Allen | Jun 2006 | B2 |
| 7070281 | Kato | Jul 2006 | B2 |
| 7072096 | Holman et al. | Jul 2006 | B2 |
| 7075707 | Rapaport et al. | Jul 2006 | B1 |
| 7083304 | Rhoads | Aug 2006 | B2 |
| 7095053 | Mazzochette et al. | Aug 2006 | B2 |
| 7112806 | Lussier | Sep 2006 | B2 |
| 7138770 | Uang et al. | Nov 2006 | B2 |
| 7144131 | Rains | Dec 2006 | B2 |
| 7157745 | Blonder et al. | Jan 2007 | B2 |
| 7161313 | Piepgras | Jan 2007 | B2 |
| 7178941 | Roberge et al. | Feb 2007 | B2 |
| 7184201 | Duncan | Feb 2007 | B2 |
| 7187484 | Mehrl | Mar 2007 | B2 |
| 7213926 | May et al. | May 2007 | B2 |
| 7234844 | Bolta et al. | Jun 2007 | B2 |
| 7246923 | Conner | Jul 2007 | B2 |
| 7247874 | Bode et al. | Jul 2007 | B2 |
| 7252408 | Mazzochete et al. | Aug 2007 | B2 |
| 7255469 | Wheatley et al. | Aug 2007 | B2 |
| 7261453 | Morejon et al. | Aug 2007 | B2 |
| 7289090 | Morgan | Oct 2007 | B2 |
| 7300177 | Conner | Nov 2007 | B2 |
| 7303291 | Ikeda et al. | Dec 2007 | B2 |
| 7319293 | Maxik | Jan 2008 | B2 |
| 7324076 | Lee et al. | Jan 2008 | B2 |
| 7325956 | Morejon et al. | Feb 2008 | B2 |
| 7342658 | Kowarz et al. | Mar 2008 | B2 |
| 7344279 | Mueller et al. | Mar 2008 | B2 |
| 7349095 | Kurosaki | Mar 2008 | B2 |
| 7353859 | Stevanovic et al. | Apr 2008 | B2 |
| 7369056 | McCollough et al. | May 2008 | B2 |
| 7382091 | Chen | Jun 2008 | B2 |
| 7382632 | Alo et al. | Jun 2008 | B2 |
| 7400439 | Holman | Jul 2008 | B2 |
| 7427146 | Conner | Sep 2008 | B2 |
| 7429983 | Islam | Sep 2008 | B2 |
| 7434946 | Huibers | Oct 2008 | B2 |
| 7436996 | Ben-Chorin | Oct 2008 | B2 |
| 7438443 | Tatsuno et al. | Oct 2008 | B2 |
| 7455435 | Mathews | Nov 2008 | B2 |
| 7476016 | Kurihara | Jan 2009 | B2 |
| 7489086 | Miskin et al. | Feb 2009 | B2 |
| 7497596 | Ge | Mar 2009 | B2 |
| 7520607 | Casper et al. | Apr 2009 | B2 |
| 7520642 | Holman et al. | Apr 2009 | B2 |
| 7521875 | Maxik | Apr 2009 | B2 |
| 7528421 | Mazzochete | May 2009 | B2 |
| 7530708 | Park | May 2009 | B2 |
| 7537347 | Dewald | May 2009 | B2 |
| 7540616 | Conner | Jun 2009 | B2 |
| 7556376 | Ishak et al. | Jul 2009 | B2 |
| 7556406 | Petroski et al. | Jul 2009 | B2 |
| 7567040 | Pong et al. | Jul 2009 | B2 |
| 7573210 | Ashdown et al. | Aug 2009 | B2 |
| 7598682 | Grajcar | Oct 2009 | B2 |
| 7598686 | Lys et al. | Oct 2009 | B2 |
| 7598961 | Higgins | Oct 2009 | B2 |
| 7605971 | Ishii et al. | Oct 2009 | B2 |
| 7619372 | Garrity | Nov 2009 | B2 |
| 7626755 | Furuya et al. | Dec 2009 | B2 |
| 7633093 | Blonder et al. | Dec 2009 | B2 |
| 7633779 | Garrity et al. | Dec 2009 | B2 |
| 7637643 | Maxik | Dec 2009 | B2 |
| 7677736 | Kasazumi et al. | Mar 2010 | B2 |
| 7678140 | Brainard et al. | Mar 2010 | B2 |
| 7679281 | Kim et al. | Mar 2010 | B2 |
| 7684007 | Hull et al. | Mar 2010 | B2 |
| 7703943 | Li et al. | Apr 2010 | B2 |
| 7705810 | Choi et al. | Apr 2010 | B2 |
| 7708452 | Maxik et al. | May 2010 | B2 |
| 7709811 | Conner | May 2010 | B2 |
| 7719766 | Grasser et al. | May 2010 | B2 |
| 7728846 | Higgins et al. | Jun 2010 | B2 |
| 7732825 | Kim et al. | Jun 2010 | B2 |
| 7748845 | Casper et al. | Jul 2010 | B2 |
| 7766490 | Harbers et al. | Aug 2010 | B2 |
| 7819556 | Heffington et al. | Oct 2010 | B2 |
| 7828453 | Tran et al. | Nov 2010 | B2 |
| 7828465 | Roberge et al. | Nov 2010 | B2 |
| 7832878 | Brukilacchio et al. | Nov 2010 | B2 |
| 7834867 | Sprague et al. | Nov 2010 | B2 |
| 7835056 | Doucet et al. | Nov 2010 | B2 |
| 7841714 | Grueber | Nov 2010 | B2 |
| 7845823 | Mueller et al. | Dec 2010 | B2 |
| 7852017 | Melanson | Dec 2010 | B1 |
| 7855376 | Cantin et al. | Dec 2010 | B2 |
| 7871839 | Lee | Jan 2011 | B2 |
| 7880400 | Zhoo et al. | Feb 2011 | B2 |
| 7889430 | El-Ghoroury et al. | Feb 2011 | B2 |
| 7906789 | Jung et al. | Mar 2011 | B2 |
| 7928565 | Brunschwiler et al. | Apr 2011 | B2 |
| 7972030 | Li | Jul 2011 | B2 |
| 7976182 | Ribarich | Jul 2011 | B2 |
| 7976205 | Grotsch et al. | Jul 2011 | B2 |
| 7984989 | Gruber | Jul 2011 | B2 |
| 8013545 | Jonsson | Sep 2011 | B2 |
| 8016443 | Falicoff et al. | Sep 2011 | B2 |
| 8040070 | Myers et al. | Oct 2011 | B2 |
| 8047660 | Penn et al. | Nov 2011 | B2 |
| 8049763 | Kwak et al. | Nov 2011 | B2 |
| 8061857 | Liu et al. | Nov 2011 | B2 |
| 8070302 | Hatanaka et al. | Dec 2011 | B2 |
| 8076680 | Lee et al. | Dec 2011 | B2 |
| 8083364 | Allen | Dec 2011 | B2 |
| 8096668 | Abu-Ageel | Jan 2012 | B2 |
| 8115419 | Given et al. | Feb 2012 | B2 |
| 8164844 | Toda et al. | Apr 2012 | B2 |
| 8182106 | Shin | May 2012 | B2 |
| 8182115 | Takahashi et al. | May 2012 | B2 |
| 8188687 | Lee et al. | May 2012 | B2 |
| 8192047 | Bailey et al. | Jun 2012 | B2 |
| 8207676 | Hilgers | Jun 2012 | B2 |
| 8212836 | Matsumoto et al. | Jul 2012 | B2 |
| 8253336 | Maxik et al. | Aug 2012 | B2 |
| 8256921 | Crookham et al. | Sep 2012 | B2 |
| 8274089 | Lee | Sep 2012 | B2 |
| 8297783 | Kim | Oct 2012 | B2 |
| 8304978 | Kim et al. | Nov 2012 | B2 |
| 8310171 | Reisenauer et al. | Nov 2012 | B2 |
| 8319445 | McKinney et al. | Nov 2012 | B2 |
| 8324808 | Maxik et al. | Dec 2012 | B2 |
| 8324823 | Choi et al. | Dec 2012 | B2 |
| 8324840 | Shteynberg et al. | Dec 2012 | B2 |
| 8331099 | Geissler et al. | Dec 2012 | B2 |
| 8337029 | Li | Dec 2012 | B2 |
| 8378574 | Schlangen et al. | Feb 2013 | B2 |
| 8384984 | Maxik et al. | Feb 2013 | B2 |
| 8401231 | Maxik et al. | Mar 2013 | B2 |
| 8405299 | Toda et al. | Mar 2013 | B2 |
| 8410717 | Shteynberg | Apr 2013 | B2 |
| 8410725 | Jacobs | Apr 2013 | B2 |
| 8446095 | Maxik et al. | May 2013 | B2 |
| 8643276 | Maxik et al. | Feb 2014 | B2 |
| 20020113555 | Lys et al. | Aug 2002 | A1 |
| 20040052076 | Mueller et al. | Mar 2004 | A1 |
| 20040093045 | Bolta | May 2004 | A1 |
| 20040119086 | Yano et al. | Jun 2004 | A1 |
| 20050189557 | Mazzochette et al. | Sep 2005 | A1 |
| 20050218780 | Chen | Oct 2005 | A1 |
| 20050267213 | Gold et al. | Dec 2005 | A1 |
| 20060002108 | Ouderkirk et al. | Jan 2006 | A1 |
| 20060002110 | Dowling et al. | Jan 2006 | A1 |
| 20060085301 | Leahy | Apr 2006 | A1 |
| 20060164005 | Sun | Jul 2006 | A1 |
| 20060232992 | Bertram et al. | Oct 2006 | A1 |
| 20060285193 | Kimura et al. | Dec 2006 | A1 |
| 20070013871 | Marshall et al. | Jan 2007 | A1 |
| 20070159492 | Lo et al. | Jul 2007 | A1 |
| 20070165193 | Kubo et al. | Jul 2007 | A1 |
| 20070188847 | McDonald et al. | Aug 2007 | A1 |
| 20070241340 | Pan | Oct 2007 | A1 |
| 20070262714 | Bylsma | Nov 2007 | A1 |
| 20080119912 | Hayes | May 2008 | A1 |
| 20080143973 | Wu | Jun 2008 | A1 |
| 20080198572 | Medendorp | Aug 2008 | A1 |
| 20080232084 | Kon | Sep 2008 | A1 |
| 20080258643 | Cheng et al. | Oct 2008 | A1 |
| 20090009102 | Kahlman et al. | Jan 2009 | A1 |
| 20090059099 | Linkov et al. | Mar 2009 | A1 |
| 20090059585 | Chen et al. | Mar 2009 | A1 |
| 20090128781 | Li | May 2009 | A1 |
| 20090160370 | Tai et al. | Jun 2009 | A1 |
| 20090231088 | Famik | Sep 2009 | A1 |
| 20090232683 | Hirata et al. | Sep 2009 | A1 |
| 20090273931 | Ito et al. | Nov 2009 | A1 |
| 20090303694 | Roth et al. | Dec 2009 | A1 |
| 20100001652 | Damsleth | Jan 2010 | A1 |
| 20100006762 | Yoshida et al. | Jan 2010 | A1 |
| 20100051976 | Rooymans | Mar 2010 | A1 |
| 20100053959 | Ijzerman et al. | Mar 2010 | A1 |
| 20100076250 | Van Woudenberg | Mar 2010 | A1 |
| 20100103389 | McVea et al. | Apr 2010 | A1 |
| 20100111369 | Lussier | May 2010 | A1 |
| 20100121420 | Fiset et al. | May 2010 | A1 |
| 20100157573 | Toda et al. | Jun 2010 | A1 |
| 20100202129 | Abu-Ageel | Aug 2010 | A1 |
| 20100213859 | Shteynberg et al. | Aug 2010 | A1 |
| 20100231131 | Anderson | Sep 2010 | A1 |
| 20100231863 | Hikmet et al. | Sep 2010 | A1 |
| 20100244700 | Chong et al. | Sep 2010 | A1 |
| 20100244724 | Jacobs et al. | Sep 2010 | A1 |
| 20100244735 | Buelow, II | Sep 2010 | A1 |
| 20100244740 | Alpert et al. | Sep 2010 | A1 |
| 20100270942 | Hui et al. | Oct 2010 | A1 |
| 20100277084 | Lee et al. | Nov 2010 | A1 |
| 20100277316 | Schlangen et al. | Nov 2010 | A1 |
| 20100302464 | Raring et al. | Dec 2010 | A1 |
| 20100308738 | Shteynberg et al. | Dec 2010 | A1 |
| 20100315320 | Yoshida | Dec 2010 | A1 |
| 20100320927 | Gray et al. | Dec 2010 | A1 |
| 20100320928 | Kaihotsu et al. | Dec 2010 | A1 |
| 20100321641 | Van Der Lubbe | Dec 2010 | A1 |
| 20110012137 | Lin et al. | Jan 2011 | A1 |
| 20110057786 | Giddens | Mar 2011 | A1 |
| 20110062888 | Bondy | Mar 2011 | A1 |
| 20110080635 | Takeuchi | Apr 2011 | A1 |
| 20110299277 | Ehara | Dec 2011 | A1 |
| 20110310446 | Komatsu | Dec 2011 | A1 |
| 20120008326 | Jou | Jan 2012 | A1 |
| 20120285667 | Maxik et al. | Nov 2012 | A1 |
| 20120286673 | Holland et al. | Nov 2012 | A1 |
| 20120286700 | Maxik et al. | Nov 2012 | A1 |
| 20130070439 | Maxik et al. | Mar 2013 | A1 |
| 20130140988 | Maxik et al. | Jun 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 101702421 | May 2010 | CN |
| 0851260 | Jul 1998 | EP |
| 1671059 | Apr 2007 | EP |
| 2 199 657 | Jun 2010 | EP |
| 2 242 335 | Oct 2010 | EP |
| 2292464 | Sep 2011 | EP |
| 2008226567 | Sep 2008 | JP |
| WO03098977 | Nov 2003 | WO |
| WO2004011846 | Feb 2004 | WO |
| WO2006001221 | Jan 2006 | WO |
| WO2009121539 | Oct 2009 | WO |
| WO 2010027459 | Mar 2010 | WO |
| WO 2010098811 | Sep 2010 | WO |
| WO 2011008251 | Jan 2011 | WO |
| WO 2011016860 | Feb 2011 | WO |
| WO 2012012245 | Jan 2012 | WO |
| WO 2012064470 | May 2012 | WO |
| WO 2012135173 | Oct 2012 | WO |
| WO 2012158665 | Nov 2012 | WO |
| PCTUS2012067916 | Dec 2012 | WO |
| Entry |
|---|
| U.S. Appl. No. 13/652,207, filed Oct. 2012, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/709,942, filed Dec. 2012, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/715,085, filed Dec. 2012, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/737,606, filed Jan. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/739,665, filed Jan. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/751,180, filed Jan. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/753,890, filed Jan. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/775,936, filed Feb. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/792,354, filed Mar. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/803,825, filed Mar. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/832,459, filed Mar. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/837,643, filed Mar. 2013, Fredric S. Maxik et al. |
| U.S. Appl. No. 13/842,875, filed Mar. 2013, Eric Holland et al. |
| 4Sevens.com, Futlight Color Temperature Adjustable Light Panel, 600x600, www.4sevens.com/product—info.php?products—id=2673, (2012). |
| Akashi, Yukio, et al., Assessment of Headlamp Glare and Potential Countermeasures: Survey of Advanced Front Lighting System (AFS), U.S. Department of Transportation, National Highway Traffic Safety Administration, Contract No. DTNH22-99-D-07005, (Dec. 2005). |
| Arthur P. Fraas, Heat Exchanger Design, 1989, p. 60, John Wiley & Sons, Inc., Canada. |
| Binnie et al. (1979) “Fluorescent Lighting and Epilepsy” Epilepsia 20(6):725-727. |
| Boeing, (Jul. 6, 2011), International Space Program, S684-13489 Revision A “ISS Interior Solid State Lighting Assembly (SSLA) Specification”, Submitted to National Aeronautics and Space Administration, Johnson Space Center, Contract No. NAS15-10000, pp. 1-60. |
| Brainard, et al., (Aug. 15, 2001), “Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor”, The Journal of Neuroscience, 21(16):6405-6412. |
| Bullough, John, et al., “Discomfort Glare from Headlamps: Interactions Among Spectrum, Control of Gaze and Background Light Level”, Society of Automotive Engineers, Inc., 2003-01-0296, (2003). |
| Charamisinau et al. (2005) “Semiconductor laser insert with Uniform Illumination for Use in Photodynamic Therapy” Appl Opt 44(24):5055-5068. |
| Derlofske, et al., “Headlamp Parameters and Glare”, Society of Automotive Engineers, Inc., 2004-01-1280, (2004). |
| ERBA Shedding Light on Photosensitivity, One of Epilepsy's Most Complex Conditions. Photosensitivity and Epilepsy. Epilepsy Foundation. Accessed: Aug. 28, 2009. http://www.epilepsyfoundation.org/aboutepilepsy/seizures/photosensitivity-/gerba.cfm. |
| Figueiro et al. (2004) “Spectral Sensitivity of the Circadian System” Proc. SPIE 5187:207. |
| Figueiro et al. (2008) “Retinal Mechanisms Determine the Subadditive Response to Polychromatic Light by the Human Circadian System” Neurosci Lett 438(2):242. |
| Gabrecht et al. (2007) “Design of a Light Delivery System for the Photodynamic Treatment of the Crohn's Disease” Proc. SPIE 6632:1-9. |
| H. A El-Shaikh, S. V. Garimella, “Enhancement of Air Jet Impingement Heat Transfer using Pin-Fin Heat Sinks”, D IEEE Transactions on Components and Packaging Technology, Jun. 2000, vol. 23, No. 2. |
| Happawana et al. (2009) “Direct De-Ionized Water-Cooled Semiconductor Laser Package for Photodynamic Therapy of Esophageal Carcinoma: Design and Analysis” J Electron Pack 131(2):1-7. |
| Harding & Harding (1999) “Televised Material and Photosensitive Epilepsy” Epilepsia 40(Suppl. 4):65. |
| Hickcox, Sweater K., et al., Lighting Research Center, “Effect of different colored background lighting on LED discomfort glare perception”, Proc. of SPIE, vol. 8484, 84840O-1, (2012). |
| Jones, Eric D., Light Emitting Diodes (LEDS) for General Lumination, an Optoelectronics Industry Development association (OIDA) Technology Roadmap, OIDA Report, Mar. 2001, published by OIDA in Washington D.C. |
| J. Y. San, C. H. Huang, M. H, Shu, “Impingement cooling of a confined circular air jet”, In t. J. Heat Mass Transf., 1997. pp. 1355-1364, vol. 40. |
| Kooi, Frank, “Yellow Lessens Discomfort Glare: Physiological Mechanism(S)”, TNO Human Factors, Netherlands, Contract No. FA8655-03-1-3043, (Mar. 9, 2004). |
| Kuller & Laike (1998) “The Impact of Flicker from Fluorescent Lighting on Well-Being, Perfiormance and Physiological Arousal” Ergonomics 41(4):433-447. |
| Lakatos (2006) “Recent trends in the epidemiology of Inflammatory Bowel Disease: Up or Down?” World J Gastroenterol 12(38):6102. |
| Mace, Douglas, et al., “Countermeasures for Reducing the Effects of Headlight Glare”, The Last Resource, Prepared for the AAA Foundation for Traffic Safety, pp. 1 to 110, (Dec. 2001). |
| Mehta, Arpit, “Map Colors of a CIE Plot and Color Temperature Using an RGB Color Sensor”, Strategic Applications Engineer, Maxim Integrated Products, A1026, p. 1-11, (2005). |
| N. T. Obot, W. J. Douglas, A S. Mujumdar, “'Effect of Semi-confinement on Impingement Heat Transfer”, Proc. 7th Int. Heat Transf. Conf., 1982, pp. 1355-1364. vol. 3. |
| Ortner & Dorta (2006) “Technology Insight: Photodynamic Therapy for Cholangiocarcinoma” Nat Clin Pract Gastroenterol Hepatol 3(8):459-467. |
| Rea (2010) “Circadian Light” J Circadian Rhythms 8(1):2. |
| Rea et al. (2010) “The Potential of Outdoor Lighting for Stimulating the Human Circadian System” Alliance for Solid-State Illumination Systems and Technologies (ASSIST), May 13, 2010, p. 1-11. |
| Rosco Laboratories Poster “Color Filter Technical Data Sheet: #87 Pale Yellow Green” (2001). |
| Shenzhen Wei Zing Xin Electronic Technology Co., ltd., Hot Color Temperature Adjustable Led Bulb Light, Alibaba.com, www.alibaba.com/product-gs/616428577/Hot—color—tempature—adjustable—led—bulb.html, (Oct. 4, 2012). |
| Sivak, Michael, et al., “Blue Content of LED Headlamps and Discomfort Glare”, The University of Michigan Transportation Research Institute, Report No. UMTRI-2005-2, pp. 1-18, (Feb. 2005). |
| S. A Solovitz, L. D. Stevanovic, R. A Beaupre, “Microchannels Take Heatsinks to the Next Level”, Power Electronics Technology, Nov. 2006. |
| Stevens (1987) “Electronic Power Use and Breast Cancer: A Hypothesis” Am J Epidemiol 125(4):556-561. |
| Stockman, Andrew, “The spectral sensitivity of the human short-wavelength sensitive cones derived from thresholds and color matches”, Pergamon, Vision Research 39, pp. 2901-2927 (1999). |
| Tannith Cattermole, “Smart Energy Class controls light on demand”, Gizmag.com, Apr. 18, 2010 accessed Nov. 1, 2011. |
| Topalkara et al. (1998) “Effects of flash frequency and repetition of intermittent photic stimulation on photoparoxysmal responses” Seizure 7(13):249-253. |
| Veitch & McColl (1995) “Modulation of Fluorescent Light: Flicker Rate and Light Source Effects on Visual Performance and Visual Comfort” Lighting Research and Technology 27:243-256. |
| Wang (2005) “The Critical Role of Light in Promoting Intestinal Inflammation and Crohn's Disease” J Immunol 174 (12):8173-8182. |
| Wilkins et al. (1979) “Neurophysical aspects of pattern-sensitive epilepsy” Brain 102:1-25. |
| Wilkins et al. (1989) “Fluorescent lighting, headaches, and eyestrain” Lighting Res Technol 21(1):11-18. |
| Yongmann M. Chung, Kai H. Luo, “Unsteady Heat Transfer Analysis of an Impinging Jet”, Journal of Heat Transfer—Transactions of the ASME, Dec. 2002, pp. 1039-1048, vol. 124, No. 6. |
| Number | Date | Country | |
|---|---|---|---|
| 20140107735 A1 | Apr 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13652207 | Oct 2012 | US |
| Child | 13832459 | US |
